NEW YORK (GenomeWeb News) - 20/20 GeneSystems said today that it has been awarded $1.9 million through the National Institute of Standards and Technology's Advanced Technology Program to develop a new technique for profiling cancer tumors that would help predict the effectiveness of chemotherapy drugs.
20/20 GeneSystems, based in Rockville, Md., said its method, called layered expression scanning-diagnostic, or LES-Dx, allows biomarkers from biopsy tissues to be mapped to a layered array that is read using “sophisticated microscopes and digital imaging techniques.”
CEO Jonathan Cohen said that when the technology is fully developed, it is expected to “significantly improve the response rates of several FDA approved targeted cancer therapies.”